Lataa...
Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
Until recently, few therapeutic options were available for patients with castration-resistant prostate cancer (CRPC). Since 2010, four new molecules with a demonstrated benefit (sipuleucel-T, cabazitaxel, abiraterone, and denosumab) have been approved in this setting, and to-date several other agent...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Research Foundation
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3364443/ https://ncbi.nlm.nih.gov/pubmed/22666217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2012.00073 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|